NCT01451736View on ClinicalTrials.gov

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 1, 2021

Study Completion Date

December 31, 2021

Conditions
Schizophrenia (Recent-onset)
Interventions
DRUG

paliperidone palmitate

long-acting injectable

DRUG

risperidone

oral

Trial Locations (1)

90095

UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

University of California, Los Angeles

OTHER

NCT01451736 - Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia | Biotech Hunter | Biotech Hunter